Evidence map›Paper›PMID 35532872›Full record

ArticleNeurochemical research2022

The Anti-Parkinson Potential of Gingko biloba-Supplement Mitigates Cortico-Cerebellar Degeneration and Neuropathobiological Alterations via Inflammatory and Apoptotic Mediators in Mice.

Olusegun G Adebayo, Wadioni Aduema, Modo U Emmanuel, Benneth Ben-Azu, Blessing O Orji, Ekam Akpakpan, Oluwakemi Rachael Adebayo, Ogechukwu G Onuoha, Abayomi M Ajayi

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Olusegun G AdebayoFaculty of Basic Medical Sciences, Department of Physiology, Neurophysiology Unit, PAMO University of Medical Sciences, Port-Harcourt, River State, Nigeria.ORCID http://orcid.org/0000-0001-6654-2564
Wadioni AduemaFaculty of Basic Medical Sciences, Department of Physiology, Bayelsa Medical University, Yenagoa, Bayelsa State, Nigeria.
Modo U EmmanuelFaculty of Basic Medical Sciences, Department of Biochemistry, PAMO University of Medical Sciences, Port-Harcourt, River State, Nigeria.
Benneth Ben-AzuFaculty of Basic Medical Sciences, Department of Pharmacology and Therapeutics, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.ORCID http://orcid.org/0000-0003-3569-3575
Blessing O OrjiFaculty of Life Sciences, Department of Biochemistry & Molecular Biology, Federal University Dutsin-Ma, Dutsin-Ma, Katsina State, Nigeria.
Ekam AkpakpanFaculty of Basic Medical Sciences, Department of Pharmacology and Therapeutics, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.
Oluwakemi Rachael AdebayoFaculty of Public Health, Department of Human Nutrition and Dietetics, University of Ibadan, Ibadan, Oyo State, Nigeria.
Ogechukwu G OnuohaFaculty of Basic Medical Sciences, Department of Physiology, Neurophysiology Unit, PAMO University of Medical Sciences, Port-Harcourt, River State, Nigeria.
Abayomi M AjayiFaculty of Basic Medical Sciences, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Oyo State, Nigeria. yomexj@yahoo.com.ORCID http://orcid.org/0000-0001-6586-0421
University of Ibadan · NGDelta State University · NGPAMO University of Medical SciencesFederal Medical Centre · NGFederal University Dutsin-Ma

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of nuclear factor erythroid 2 related factor 2 (Nrf2) associated with the suppression of various oxido-inflammatory pathways and the controller of several gene expressions involving "antioxidant response elements" (AREs) in their promoters to mediate and restores homeostatic functions is now considered as one of the main switch regulating the immune response, and it is also now involved in inflammatory cascade in PD. Whether therapeutic approach using Ginkgo biloba would have significant protective effects against cortico-cerebellar dopaminergic degeneration in rotenone-induced mice remains unknown. In this present study, we studied the therapeutic effects of Ginkgo biloba-supplement (Gb-S) administration in cortico-cerebellar dopaminergic degeneration. The results revealed that treatment with Gb-S suppresses cognitive decline and neuromuscular incompetence in the mice, abated tyrosine hydroxylase depletion and synucleinopathy development in the cortico-cerebellar neurons of the mice before and after rotenone induction. However, our data further shows increase Nrf2 immunoexpression with decrease oxido-nitrergic and neuroinflammatory release, increase cholinergic enzyme activity and downregulated executioner caspase-3 that may mediate cortico-cerebellar apoptosis. Also, the loss of cortico-cerebellar neurons was attenuated, marked by increase in dendritic spine length and width with numerous viable neurons. Overall findings suggest that Gb-S could be a potential pharmacotherapeutic candidate providing a strong protection for cortico-cerebellar neurocellular substances and against Parkinsonism-like non-motor and motor symptoms.

Indexed as

Ginkgo bilobaNeurodegenerative DiseasesNeuroprotective AgentsPlant PreparationsAnimalsApoptosisDisease Models, AnimalDopamineMiceNF-E2-Related Factor 2Parkinson DiseaseRotenoneDopamineNeuroprotective AgentsNF-E2-Related Factor 2Plant PreparationsRotenoneAntioxidantCortico-cerebellumGinkgo bilobaNeuroinflammationNrf2Parkinson’s disease

Identifiers

PMID35532872
OpenAlexW4229368368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.